Epithelioid Inflammatory Myofibroblastic Sarcoma Responsive to Surgery and an ALK Inhibitor in a Patient with Panhypopituitarism

Kotomi Kurihara-Hosokawa; Isao Kawasaki; Anna Tamai; Yoko Yoshida; Yosuke Yakushiji; Hiroki Ueno; Mariko Fukumoto; Hiroko Fukushima; Takeshi Inoue; Masayuki Hosoi

doi:10.2169/internalmedicine.53.2546

CASE REPORTS

Epithelioid Inflammatory Myofibroblastic Sarcoma Responsive to Surgery and an ALK Inhibitor in a Patient with Panhypopituitarism

Kotomi Kurihara-Hosokawa, Isao Kawasaki, Anna Tamai, Yoko Yoshida, Yosuke Yakushiji, Hiroki Ueno, Mariko Fukumoto, Hiroko Fukushima, Takeshi Inoue, Masayuki Hosoi

Author information

Kotomi Kurihara-Hosokawa
Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
Isao Kawasaki
Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
Anna Tamai
Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
Yoko Yoshida
Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
Yosuke Yakushiji
Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
Hiroki Ueno
Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
Mariko Fukumoto
Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
Hiroko Fukushima
Department of Pathology, Osaka City General Hospital, Japan
Takeshi Inoue
Department of Pathology, Osaka City General Hospital, Japan
Masayuki Hosoi
Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan

Keywords: epithelioid inflammatory myofibroblastic sarcoma (EIMS), RANBP2-ALK fusion gene, ALK inhibitor, inflammatory myofibroblastic tumor (IMT)

JOURNAL OPEN ACCESS

2014 Volume 53 Issue 19 Pages 2211-2214

DOI https://doi.org/10.2169/internalmedicine.53.2546

Details

Abstract

We encountered a case of epithelioid inflammatory myofibroblastic sarcoma (EIMS) originating from an abdominal organ that rapidly regrew twice. The patient underwent two surgeries. Large tumors grew within three months after the second surgery. The patient subsequently received chemotherapy with an anaplastic lymphoma kinase (ALK) inhibitor. Although EIMS has a poor prognosis, the patient continues to be alive with disease 14 months after surgical treatment and the administration of the ALK inhibitor.

Corresponding author

Register with J-STAGE for free!